PURPOSE: [(11)C]T-773 is a new radioligand for positron emission tomography (PET) targeting the phosphodiesterase 10A enzyme (PDE10A). PDE10A is highly expressed in the striatum by medium spiny neurons, and it has been demonstrated to be involved in the regulation of striatal signaling through the reduction of medium spiny neuronal sensitivity towards glutamatergic excitation. PDE10A is associated with Parkinson's disease and different neuropsychiatric disorders such as Huntington's disease, obsessive-compulsive disorders (OCD) and schizophrenia. Studies have indicated that the inhibition of PDE10A may represent a novel therapeutic approach to the treatment of the aforementioned diseases characterized by the reduced activity of medium spiny neurons. An appropriate PET radioligand for PDE10A would help to facilitate drug development and drug evaluation. PROCEDURES: We have evaluated the [(11)C]T-773 ligand in PDE10A knockout mice (heterozygous [HET] and homozygous [HOM]) as well as in normal control animals (WILD) with PET. RESULTS: The regional percent standardized uptake values (%SUV; mean ± SD) in the striatum were 48.2 ± 1.0 (HOM), 63.6 ± 5.3 (HET) and 85.1 ± 6.3 (WILD). Between each animal group the striatal %SUV values were significantly different (p < 0.0001). The striatal BPND values (mean ± SD) were 0.0 ± 0.0 (HOM), 0.14 ± 0.07 (HET) and 0.56 ± 0.15 (WILD). The BPND values were significantly lower in homozygous and heterozygous animals compared to wild type (p < 0.0001). CONCLUSIONS: The novel PDE10A radioligand [(11)C]T-773 shows increased signals with higher levels of PDE10A and acceptable binding in the striatum in control animals compared to knockout mice.
PURPOSE: [(11)C]T-773 is a new radioligand for positron emission tomography (PET) targeting the phosphodiesterase 10A enzyme (PDE10A). PDE10A is highly expressed in the striatum by medium spiny neurons, and it has been demonstrated to be involved in the regulation of striatal signaling through the reduction of medium spiny neuronal sensitivity towards glutamatergic excitation. PDE10A is associated with Parkinson's disease and different neuropsychiatric disorders such as Huntington's disease, obsessive-compulsive disorders (OCD) and schizophrenia. Studies have indicated that the inhibition of PDE10A may represent a novel therapeutic approach to the treatment of the aforementioned diseases characterized by the reduced activity of medium spiny neurons. An appropriate PET radioligand for PDE10A would help to facilitate drug development and drug evaluation. PROCEDURES: We have evaluated the [(11)C]T-773 ligand in PDE10A knockout mice (heterozygous [HET] and homozygous [HOM]) as well as in normal control animals (WILD) with PET. RESULTS: The regional percent standardized uptake values (%SUV; mean ± SD) in the striatum were 48.2 ± 1.0 (HOM), 63.6 ± 5.3 (HET) and 85.1 ± 6.3 (WILD). Between each animal group the striatal %SUV values were significantly different (p < 0.0001). The striatal BPND values (mean ± SD) were 0.0 ± 0.0 (HOM), 0.14 ± 0.07 (HET) and 0.56 ± 0.15 (WILD). The BPND values were significantly lower in homozygous and heterozygous animals compared to wild type (p < 0.0001). CONCLUSIONS: The novel PDE10A radioligand [(11)C]T-773 shows increased signals with higher levels of PDE10A and acceptable binding in the striatum in control animals compared to knockout mice.
Authors: Istvan Szanda; Jane Mackewn; Gergely Patay; Peter Major; Kavitha Sunassee; Gregory E Mullen; Gabor Nemeth; York Haemisch; Philip J Blower; Paul K Marsden Journal: J Nucl Med Date: 2011-10-03 Impact factor: 10.057
Authors: C J Schmidt; D S Chapin; J Cianfrogna; M L Corman; M Hajos; J F Harms; W E Hoffman; L A Lebel; S A McCarthy; F R Nelson; C Proulx-LaFrance; M J Majchrzak; A D Ramirez; K Schmidt; P A Seymour; J A Siuciak; F D Tingley; R D Williams; P R Verhoest; F S Menniti Journal: J Pharmacol Exp Ther Date: 2008-02-20 Impact factor: 4.030
Authors: Judith A Siuciak; Douglas S Chapin; John F Harms; Lorraine A Lebel; Sheryl A McCarthy; Leslie Chambers; Alka Shrikhande; Stephen Wong; Frank S Menniti; Christopher J Schmidt Journal: Neuropharmacology Date: 2006-06-15 Impact factor: 5.250
Authors: Sofie Celen; Michel Koole; Meri De Angelis; Ivan Sannen; Satish K Chitneni; Jesus Alcazar; Stefanie Dedeurwaerdere; Dieder Moechars; Mark Schmidt; Alfons Verbruggen; Xavier Langlois; Koen Van Laere; José Ignacio Andrés; Guy Bormans Journal: J Nucl Med Date: 2010-09-16 Impact factor: 10.057
Authors: Jinda Fan; Xiang Zhang; Junfeng Li; Hongjun Jin; Prashanth K Padakanti; Lynne A Jones; Hubert P Flores; Yi Su; Joel S Perlmutter; Zhude Tu Journal: Bioorg Med Chem Date: 2014-03-26 Impact factor: 3.641
Authors: Olivier Barret; David Thomae; Adriana Tavares; David Alagille; Caroline Papin; Rikki Waterhouse; Timothy McCarthy; Danna Jennings; Ken Marek; David Russell; John Seibyl; Gilles Tamagnan Journal: J Nucl Med Date: 2014-06-04 Impact factor: 10.057
Authors: S Celen; M Koole; M Ooms; M De Angelis; I Sannen; J Cornelis; J Alcazar; M Schmidt; A Verbruggen; X Langlois; K Van Laere; J I Andrés; G Bormans Journal: Neuroimage Date: 2013-05-09 Impact factor: 6.556
Authors: Mohammed K Hankir; Mathias Kranz; Thorsten Gnad; Juliane Weiner; Sally Wagner; Winnie Deuther-Conrad; Felix Bronisch; Karen Steinhoff; Julia Luthardt; Nora Klöting; Swen Hesse; John P Seibyl; Osama Sabri; John T Heiker; Matthias Blüher; Alexander Pfeifer; Peter Brust; Wiebke K Fenske Journal: EMBO Mol Med Date: 2016-07-01 Impact factor: 12.137